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ABSTRACT
Glioblastoma presents as a heterogeneous disease with poor prognosis despite
the use of multimodal therapy. Analysis of genomic DNA changes between initial
diagnosis and recurrence in response to standard treatment protocols would enhance
understanding of disease progression and better inform new treatment strategies. A
cohort of 21 patients with primary glioblastoma were examined between diagnosis
and first recurrence. This study presented a rare opportunity to characterize molecular
alterations in tumors observed in three patients who received no therapeutic
intervention, other than surgery, offering a unique control. We focused this study
by comparing the dynamic mutation profiles between the primary tumors and their
matched recurrent counterparts. Molecular profiling of tumors was performed using
multiplexed targeted deep sequencing of 409 well characterized cancer-associated
genes, achieving a mean read depth of 1272 x. Three levels of evidence suggested
an evolutionary pattern consistent with a response to therapy-mediated selection
pressures exists in treated patients: 1) variant burden was reduced in recurrent
tumors, 2) neutral evolutionary dynamics apparent in untreated tumors shifted
toward a non-neutral mode of evolution in treated patients at recurrence, and 3) the
recurrent tumor of one patient displayed an increased mutation rate attributable to
a temozolomide-associated hypermutator phenotype. Our observations suggest that
current treatment modalities are likely to fail in achieving long term remission with
the majority of relapse samples containing distinct mutations when compared to
primary diagnostic samples.

www.impactjournals.com/oncotarget

7844

Oncotarget

INTRODUCTION

hence following a 1/f power-law distribution [6]. Clonal
selection appears to have occurred as an early event
prior to tumor growth and the acquisition of numerous
passenger mutations results in intratumoral heterogeneity.
The contrasting notion is that expansion of subclones is
influenced by strong selection pressures to adapt to the
tumor microenvironment or in response to treatment
modalities. The concept of neutral tumor evolution has
not been examined in detail in GBM.
In the current study we have explored a welldefined group of clinically annotated primary GBM tumor
samples to examine the natural history of mutational
alterations within tumors during progression and in
response to treatment. Our results emphasize the inherent
heterogeneity of primary GBM at a genomic level and
show that GBM is an evolving tumor with or without
therapeutic intervention. We explored the concept of
“effectively-neutral” evolutionary dynamics in the context
of untreated and treated primary GBM, showing a shift
toward non-neutral evolutionary expansion of subclonal
variants after treatment with radiochemotherapy.

Fundamental knowledge of the biology of recurrent
glioblastoma (GBM) has been limited until recently.
This has been due to the comparatively low numbers
of patients (20–30%) undergoing surgery at recurrence
due to limited evidence of clinical benefit [1, 2], thus
limiting opportunities for molecular characterization
of the processes associated with disease resistance and
recurrence.
In the setting of low grade glioma, hypermutation
induced by temozolomide (TMZ) treatment was
observed in a subset of astrocytomas at recurrence [3].
Temozolomide-associated mutations were identified that
target the retinoblastoma tumor suppressor (RB) pathway,
activate AKT-mTOR signaling and promote tumor growth
and metastasis. Interestingly, microdissection revealed that
these mutations were confined to regions with mTORC1
activation and high Ki-67 index, suggesting that mutations
induced by TMZ conferred a growth advantage. Whether
these observations are transferable to primary GBM
remains to be explored.
Using data from The Cancer Genome Atlas (TCGA)
and 21 paired primary and recurrent GBM, Kim et al. [4]
inferred two models for clonal evolution at recurrence.
In the ancestral cell origin model, dominant clones in
the primary tumor disappear in response to therapy. New
mutations are then acquired in refractory ancestral cells
causing cell proliferation and tumor recurrence. In the
clonal evolution model, major primary disease clones
survive treatment and continue to grow. Critically, it
was found that key alterations in GBM driver genes
frequently present in primary tumors were unlikely to
be initiating mutations as they were often absent in the
recurrent tumor, mutated at a different base or deleted/
ampliﬁed with different copy number breakpoints
suggesting “intratumoral evolutionary pressures resulting
in convergent evolutionary events”. This emphasizes
the importance of detailing the characteristics of disease
relapse in order to better understand the true ancestral
alterations driving GBM development and identify
potential therapeutic targets.
Wang et al. [5] analyzed longitudinal genomic and
transcriptomic data from 114 patients, including a mix
of primary and secondary GBM initial and recurrent
tumor pairs. A highly branched evolutionary pattern was
observed in which 63% of patients exhibited different
expression-based subtypes at diagnosis and relapse.
Hypermutation of highly expressed genes was detected
in 15% of tumors at relapse, with a clear mutational
signature.
Neutral tumor evolution describes the distribution
of variant allele frequencies (VAFs) within a tumor and
predicts that, although individual subclones possess unique
mutational patterns, they expand at similar rates and
accumulate linearly with the inverse of their frequency,
www.impactjournals.com/oncotarget

RESULTS
Sample characteristics
Our study focused on a group of 21 patients
(cohort 1) diagnosed with primary GBM, including two
glioblastoma with primitive neuronal component (GBMPNC) histology at diagnosis. Within this cohort, three
patients had elected not to receive any intervention other
than surgery and the remaining 18 patients received
standard concomitant RT and TMZ [7]. Twelve of
the treated patients then received four to six cycles
of adjuvant TMZ and three received varied adjuvant
therapy as described in Table 1. A variety of treatments,
including carmustine, carboplatin and bevacizumab were
administered as salvage therapy to some patients after the
second surgical resection.

Mutational and key pathway analysis
Specimens from cohort 1 exhibited a pattern of
variants in coding regions previously well described for
primary GBM [8, 9]. As matched normal specimens were
unavailable for this cohort, variant calls may include low
frequency and rare single nucleotide polymorphisms
(SNPs). The signaling pathways with nonsynonymous or
splice site variants detected in key genes are summarized
in Figure 1, along with MGMT methylation status.
Specifically, in their initial tumors, non-synonymous and
splice site variants in EGFR occurred in four patients
(19%) and eight patients (38%) harbored PTEN variants,
38% of which were single nucleotide variations (SNVs)
resulting in premature stop codons and protein truncation
(p.R130*, p.R223*, p.R335*). The overall incidence of
7845
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Table 1: Summary of patient clinical data
Patient

Gender

Age at
diagnosis
(years)

Primary
diagnosis

Diagnosis of
recurrence

1

F

50

GBM

GBM

2
3

F

44

GBM

M

49

GBM

4

M

7

Treatment prior to second surgery

Time to
recurrence
(months)

Survival
(months)

none

19

36.4

GBM

Concomitant RT/TMZ only

3

22.0

GBM

Concomitant RT/TMZ and 4 cycles adjuvant TMZ

8

9.9a

35

GBM-PNC GBM

Concomitant RT/TMZ and standard adjuvant TMZ

11

12.2

F

62

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

7

11.9

8

M

33

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

9

18.6

9

M

51

GBM

GBM

Concomitant RT/TMZ and adjuvant AVAglio (+/-BVZ)

9

16.4

10

M

57

GBM

GBM

Concomitant RT/TMZ and 2 cycles adjuvant AVAglio (+/-BVZ)

5

17.1

11

M

74

GBM

GBM

Concomitant RT/TMZ only

3

7.2

12

M

66

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

11

15.9

14

M

56

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

14

17.6

15

F

33

GBM

GBM

Concomitant RT/TMZ only

8

14.6

16

M

39

GBM

GBM

Concomitant RT/TMZ and 4 cycles adjuvant TMZ

9

14.5

18

F

63

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

7

14.3

19

M

67

GBM

GS

Concomitant RT/TMZ and standard adjuvant TMZ, then 2nd line BVZ 8 months

18

19.5

20

F

57

GBM

GBM

Concomitant RT/TMZ and 9 cycles adjuvant AVAglio (+/-BVZ)

15

19.3

21

F

48

GBM-PNC GBM-PNC

Concomitant RT/TMZ and standard adjuvant TMZ

24

29.2

22

M

43

GBM

GBM

Concomitant RT/TMZ and 4 cycles adjuvant TMZ

10

15.1

26

M

66

GBM

GBM

Concomitant RT/TMZ and standard adjuvant TMZ

8

30.6

28

M

54

GBM

GBM

none

2

13.2

29

M

34

GBM

GBM

none

3

13.8

GBM Glioblastoma; GBM-PNC Glioblastoma with primitive neuronal component; GS Gliosarcoma; BVZ bevacizumab;
AVAglio Phase 3 trial of BVZ plus TMZ and RT in newly diagnosed GBM
a
Censored

TP53 variants was 33%, detected in seven patients who
each possessed distinct SNVs. These were all found to
be annotated in the Catalogue of Somatic Mutations in
Cancer (COSMIC) [10].
Of significant interest were variants in the mismatch
repair (MMR) pathway that occurred in 52% of patients in
one or both samples. We observed that in the patients who
received RT and TMZ, variants present in MSH2, MSH6,
PMS1 or PSM2 at diagnosis were also present at recurrence
(Figure 1). Similarly, one of three untreated patients had a
variant in MSH2 that was also present at recurrence. There
were no MMR pathway variants unique to diagnosis in
any patient and no variants unique to recurrence in the
untreated patients. In contrast, in treated patients a number
of private variants appeared at recurrence in MLH1, MSH6
and PSM2, generally at a frequency of less than 30%
suggesting the emergence of subclones in this pathway
undetected at diagnosis. Although there was no significant
difference in the number of variants detected in key MMR
genes in treated and untreated patients overall, the sample
in which the variants occurred was noteworthy and was
a factor that approached statistical significance (F2, 59 =
www.impactjournals.com/oncotarget

3.13, p = 0.051). More specifically, the absence of MMR
variants unique to diagnosis, compared to the numbers
present in both samples or uniquely at relapse, fell just
beyond statistically significant parameters using post-hoc
tests (t(20) = -2.29, p = 0.065 and t(20) = 2.03, p = 0.113
for shared and unique to relapse comparison respectively;
Supplementary Figure 1A).
In the case of IDH1 we identified six patients with
variants common to both their diagnosis and relapse
samples, none of which were the well characterized
activating substitution at arginine 132 (IDH1R132H+)
seen in lower grade tumors. Given that somatic IDH1
variants exclusively alter R132 in GBM as presented in
TCGA, these detected variants are likely low frequency
or rare SNPs. In this cohort we identified a missense
c.548 A > G SNV in Patient 1 (Untreated) and Patient
3 (Treated), resulting in a p.Y183C amino acid change
predicted as functionally damaging or deleterious using
Sorting Tolerant from Intolerant (SIFT) [11] or Protein
Variation Effect Analyzer (PROVEAN) [12] scores
respectively. This variant is recorded in the NCBI SNP
database (dbSNP rs34599179) as a rare SNP with a minor
7846
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In primary GBMs standard radiochemotherapy
did not impact the burden of mutations in
recurrent tumors with the exception of one
patient

allele frequency (MAF) of 0.36%. Patients 14, 15, 16, 26
(All Treated) each had a c.532 G > A (p.V178I) missense
variant predicted to be tolerated/neutral. This is classified
as a low frequency SNP (rs34218846; MAF=4.93%)
and is present in COSMIC (COSM97131), confirmed as
somatic for thyroid and lymphoid studies [13]. To date a
functional role remains unclear. There was also a deletion
in the 5’ splice site of exon 9 (NG_023319.2:g.28927delC)
in Patient 15, a rare SNP (rs533101765) with a MAF of
0.08%.
Methylation of MGMT was detected in the primary
tumors of five patients and the methylation persisted at
recurrence in four of these patients. An additional patient
was MGMT methylated uniquely at recurrence (Figure 1).
Only one recurrent patient sample (patient 21) showed a
pattern consistent with the MMR-defective hypermutator
phenotype [14–17]. Similar to previous reports, MGMT
was methylated and multiple DNA MMR genes (MLH1
and PMS2) were mutated in the recurrent tumor, but these
variants were not present at diagnosis. Variants in IDH1 or
IDH2 were not detected in this patient (Figure 1).

When considering the total burden of genetic
variation detected, including intronic, splice site, nonsynonymous and synonymous exonic variants (patient
21 was excluded as an outlier; p ≤ 0.001), in treated
patients there was an average of 120 variants detected in
newly diagnosed and 103 variants in recurrent samples.
We found an average of 49 variants to be unique to
diagnosis and 32 to be unique to recurrence. In the three
untreated patients a similar pattern of mutational burden
was observed with an average of 117 and 115 variants
detected in diagnosis and recurrence samples respectively.
An average of 37 variants were unique to diagnosis and 35
were unique to recurrence (Figure 2A). In contrast, patient
21 was found to have 54 variants unique to diagnosis and
142 unique to the recurrent tumor (Figure 2A). Excluding
patient 21, the mean number of variants was significantly

Figure 1: Patterns of mutations in key signaling pathway genes were consistent with previously described traits of
primary GBM. OncoPrint summarizing the non-synonymous and splice site variants detected by targeted deep sequencing in both
diagnostic (open circles) and relapse (closed circles) specimens for each of the 21 patients. Specimens with methylation of MGMT are
noted in red.
www.impactjournals.com/oncotarget
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(F1,113 = 3.98, p = 0.002; Figure 3A). However, no clear
difference was identified when comparing untreated to
treated patients after adjusting for the type of single base
substitution (F1,113 = 1.85, p = 0.176; Figure 3B).
We
observed
TMZ
treatment-induced
hypermutation, previously described in secondary
GBM [3, 18], in the recurrent tumor of only patient 21.
Approximately 72% of the SNVs identified at recurrence
were classified as TMZ-associated C:G > T:A variants
unique to relapse and 73% of these occurred at CpC
and CpT dinucleotides, characteristic of TMZ-induced
hypermutation (Supplementary Table 3). Review of the
pathology status did suggest this patient was histologically
distinct as a GBM-PNC and the patient survived for an
extended period of 29 months.
In these analyses we compared the total number and
proportions of each dinucleotide context of these variants
(Figure 3C; Supplementary Table 3) and, excluding patient
21, we could not discern any enrichment for these TMZassociated transitions in any patient.

higher in diagnosis samples compared to relapse (F1,37 =
6.44, p = 0.016) and there was no significant difference
between the treated and untreated patients (F1,37 = 0.22, p
= 0.641; Figure 2B). The number of variants observed also
varied by sample type (F2,56 = 52.87, p < 0.001), with a
significantly higher number of variants found to be shared
between matched samples than unique to either sample
(t(19) = 6.36, p < 0.001 and t(19) = 10.18, p < 0.001 for
unique to diagnosis and unique to relapse comparison
respectively), which may in part be due to the presence of
low frequency or rare SNPs. Moreover, the mean number
of variants unique to relapse was also significantly lower
than those unique to diagnosis (t(19) = 3.82, p = 0.001).
There was no observable effect of treatment on this pattern
of variants (Supplementary Figure 1B, 1C; Supplementary
Table 1).
Considering only coding region variants that were
non-synonymous and splice site variants and therefore
of potentially more functional significance (Figure 2C;
Supplementary Table 1; Supplementary Table 2), once
again no difference in variant burden was observed
between treated and untreated patients (F1,37 = 0.00, p =
0.996), again with the exclusion of patient 21. Significantly
fewer variants were detected at recurrence (F1,37 = 14.28, p
= 0.001; Figure 2D). The mean number of variants unique
to relapse remained lower than those unique to diagnosis
(t(19) = 5.64, p < 0.001) and again there was no observable
effect of treatment (Supplementary Figure 1D, 1E).
In line with recent data [4], the presence of nonsynonymous TP53 variants was associated with a higher
incidence of low frequency (VAF < 0.4) SNVs in recurrent
tumors (F1,38 = 21.73, p < 0.001; Figure 2E). Tumors
were designated TP53 mutated if they possessed a nonsynonymous variant that was predicted to be damaging/
deleterious by SIFT/PROVEAN. All of these variants
were also previously confirmed as somatic in other
glioma tumor samples presented in COSMIC. There was
no significant difference between TP53 wildtype and
mutant tumors at diagnosis, however, the disproportionate
variant numbers overall between primary and recurrent
specimens was not observed in TP53 mutated tumors and
was confined to low frequency variants in TP53 wildtype
tumors (Figure 2E; Supplementary Figure 1F). These
effects were not evident for high frequency variants (VAF
≥ 0.4) (Figure 2E; Supplementary Figure 1G).

Neutral tumor evolution was prominent in
untreated GBM and a shift toward non-neutral
evolutionary dynamics was evident in subclones
after treatment.
Leukocytes unmethylation to infer tumor purity
(LUMP) analysis, as detailed previously [19], was
undertaken for 20 of the matched samples in cohort
1 (patient 12 was excluded due to sample quality
limitations). A sample purity threshold of 55% excluded
seven diagnosis and six recurrent samples, which included
three of six specimens from untreated patients (Figure
4A; Supplementary Table 4). To account for the potential
confounding effects of purity, the VAFs detected in the
remaining specimens were corrected to adjust for varying
levels of normal tissue contamination [6].
Neutral evolution was evident in the tumors of
patients at diagnosis when subclonal variants and their
frequency were analyzed collectively. As predicted by
the neutral evolution model, the cumulative distribution
of subclonal variants was found to be linear with the
inverse of their frequency. A strong fit to the neutral
evolution model with an R2 value of 0.9897 (Figure
4B) was observed overall for primary tumors and a
shift to non-neutral evolutionary dynamics was seen at
recurrence (R2 = 0.9571), suggesting that the selective
pressures of radiochemotherapy influenced subclonal
variant expansion. Excluding the relapse sample of
patient 21 from this analysis, due to its TMZ-associated
hypermutated status, resulted in a slight increase in
the goodness-of-fit for the neutral evolution model at
recurrence (R2 = 0.9602; Figure 4B). A non-neutral
evolutionary dynamic persisted suggesting that selection
pressures at recurrence in treated patients were not unique
to the MMR-defective hypermutator phenotype.

Treatment with TMZ was found to have little
effect on the generation of sequence variation in
recurrent GBM.
A recognized signature of TMZ-induced
mutagenesis is the production of C > T/G > A transitions,
predominantly occurring at CpC and CpT dinucleotides.
Analysis of the distribution of single base substitutions
unique to recurrence across all patients revealed a
higher number of C > T/G > A base transitions overall
www.impactjournals.com/oncotarget
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Figure 2: The burden of mutations was not heavily impacted by treatment with RT and TMZ. (A) The number of variants

detected overall in untreated and treated patients, presented according to the specimen/s in which they were observed. (B) Box plot showing
the mean number of variants by treatment or sample type. Patient 21 was excluded as an outlier from this analysis. (C) Coding region
variants defined as non-synonymous and splice site mutations, presented as shared or unique to either diagnosis or relapse specimens.
(D) Box plot showing the mean number of non-synonymous and splice site variants by treatment (treated vs untreated) or sample type
(diagnosis vs relapse). Patient 21 was excluded from this analysis. (E) The presence of SNVs was analyzed according to the TP53 status of
tumor specimens. TP53 wildtype tumors (WT) were compared to TP53 mutant tumors (mut), which were defined as those that contained
non-synonymous TP53 variants. SNVs were designated low VAF (< 0.4) or high VAF (≥ 0.4) and were tallied separately for the diagnosis
and relapse specimens of each patient (excluding the relapse sample of patient 21). Untreated patients are depicted as open squares and
treated patients as closed circles. The mean and 95% confidence intervals are also shown. A two-way analysis of variance was performed
using a general linear model and p-values for significant differences (p ≤ 0.001) are displayed.
www.impactjournals.com/oncotarget

7849

Oncotarget

Due to the targeted nature of this high-depth
sequencing analysis, goodness-of-fit measures using
the stringent threshold of R2 > 0.98 for defining neutral
evolution in individual specimens may undercall neutrality
as low numbers of variants with which to fit the model
may lead to a poorer fit to the data [6]. In addition
to discriminating between neutral and non-neutral
evolution in primary tumors, we were able to compare
the dynamics of subclonal variants between diagnosis
and first recurrence, reflecting treatment influences.
Determination of individual goodness-of-fit measures for
each sample showed that in paired diagnosis and relapse
specimens from the same patient the neutral evolution
model fit decreased in 8 of 10 patients (Figure 4C).
Subclonal variants in 5 of 13 primary tumor specimens
achieved R2 values above 0.96. The mean R2 value of
samples at diagnosis was not significantly different
from an R2 value of 0.96 (M = 0.9477, 95% CI [0.9314,
0.9640], t(12) = -1.65, p = 0.125). Whilst collectively
primary samples displayed effectively-neutral evolution,
analysis of specimens individually failed to designate
any samples as evolving neutrally. The mean R2 value
obtained for patients at diagnosis was significantly lower
than the stringent R2 threshold of 0.98 (t(12) = -4.832, p
= 0.001). In contrast to diagnostic samples, the mean R2
value of relapse samples was significantly lower than an
R2 value of 0.96 (M = 0.89654, 95% CI [0.8494, 0.9414],
t(12) = -3.06, p = 0.01). At recurrence, all 13 samples
were classified as undergoing non-neutral evolutionary
expansion of subclonal variants. A further shift away from
a neutral model fit was evident in the majority of samples
at recurrence with significantly higher R2 values observed
for diagnosis compared to relapse specimens (F1,24 = 5.06,
p = 0.034; Figure 4D). Excluding the recurrent sample
of patient 21 does not substantially alter the significance
of the difference observed between samples at diagnosis
and relapse (F1,23 = 4.89, p = 0.037). Neutral evolution of
subclonal variants was evident in the primary tumor of
Patient 21 (R2 > 0.9783). However, in the recurrent tumor
with TMZ-associated hypermutation non-neutral dynamics
dominate (R2 > 0.9077; Figure 4E). These observations
suggest that radiochemotherapy exerts selective pressure
influencing subclonal variant dynamics in treated tumors.
In an attempt to verify these observations in a
larger cohort, publicly available tumor datasets were
interrogated for purity and VAF information. Two sets
of data were analyzed which included selected samples
(cohort 2) from TCGA [20] and additional samples (cohort
3) previously collated and reported by Wang et al. [5].
A total of 408 samples from TCGA were considered,
including 12 recurrent specimens. Of these, 175 were
evaluated for neutral tumor evolution with data from 93
primary samples satisfying final inclusion criteria for
analysis (Supplementary Table 4). Criteria for exclusion
were absent or low purity estimations as determined
by the ABSOLUTE computational method [21] and
www.impactjournals.com/oncotarget

insufficient numbers of subclonal variants identified
for analysis. Cohort 3 consisted of 10 specimens, from
six primary and four recurrent tumors. A total of 142
samples were excluded for the above-mentioned reasons.
The remaining 10 samples were all primary GBM with
no history of lower grade glioma, nine of which were
from the INCB cohort from the Besta Brain Biobank,
previously published by Wang et al. [5]. The final sample
was from the SMC cohort from Seoul National University
Hospital, previously reported by Kim et al. [22]. This
exercise highlighted the challenges of analyzing disparate
datasets with absent parameters or collected using varied
methodology. Approaches varied for both sequencing,
including platform and depth of coverage, and inference
of tumor purity. The three cohorts were therefore not
directly comparable, limiting observations to three
smaller individual cohorts. The higher rates of exclusion
to obtain cohorts 2 and 3 may also be reflective of broader
GBM subtype representation within the cohorts, and the
potential purity differences between them [19].
The effects of including samples to a range of
minimum purity levels was analyzed in the larger group
(cohort 2) of primary samples from TCGA (Figure
5A). Whilst lowering the acceptable minimum purity
value increased the number of samples included in
the analysis, it resulted in poorer neutral evolution
model fits. In comparison, use of purity-adjusted VAFs
revealed more similar model fits (Mdn = 0.9738, 95%
CI [0.9647, 0.9824]), with 44% of samples dominated by
neutral evolutionary dynamics as defined by an R2 value
of at least 0.98. There seemed to be a shift away from
characteristically neutral evolution in recurrent samples
(Mdn = 0.9011, 95% CI [0.8098, 0.9606]). However,
the analysis was limited to only eight samples with no
available purity data, and therefore offers little insight.
Similarly, cohort 3 consisted of 10 specimens with purity
data enabling adjustment of VAFs prior to assessment of
a neutral evolution model fit. The R2 model fit values at
recurrence again were seemingly lower than at diagnosis
(Mdn = 0.8574, 95% CI [0.7542, 0.9382] at diagnosis vs
Mdn = 0.7728, 95% CI [0.6685, 0.9032] at recurrence),
but this difference did not reach statistical significance (p
= 0.281; Figure 5B).
Together, these data suggest that there is a stronger
fit to a neutral evolution model in GBM samples at
diagnosis, shifting quickly to dynamics reflecting selection
pressures at recurrence.

DISCUSSION
Our study is unique and adds several new findings to
the field. We were able to interrogate untreated (n = 3) and
treated (n = 18) patients and confirmed the dynamic nature
of genomic alterations in GBM. The instability of genomic
alterations after GBM recurrence relative to GBM primary
tumor samples was evident, even in the absence of any
7850

Oncotarget

therapy. In contrast to data published by others in primary
GBM [4, 5] and previously described in secondary
GBM [3], we only observed TMZ treatment-induced
hypermutation in the recurrent tumor of one patient.
Consistent with previous reports, the majority of variants
were of low VAF and occurred in multiple DNA MMR
genes. MGMT was also methylated in both the primary
tumor and at recurrence. In contrast to other studies, both
were IDH wildtype [3, 22] providing one example against
the notion that the lack of hypermutation in primary GBM
is due to a fundamental difference between IDH mutant
(secondary) and IDH wildtype (primary) GBM [23].
Furthermore, when closely examining the total number
and proportions of TMZ-associated variants in each
dinucleotide context, we could not discern enrichment
for these TMZ-associated transitions in any patients other
than the one patient. This suggests a different evolution of
variants or active repair of such variants in the majority of
primary GBM after TMZ treatment.
A perfectly neutral evolution of subclonal variants
results in a constant allelic frequency of each variant as

the tumor expands (Figure 6). The growth rate of cells that
possess one or more variants is no different from cells that
do not. New variants that arise expand at the same rate
with no fitness advantage. After therapy at recurrence a
further shift toward non-neutral modes of evolution was
observed. A differential response to therapy and treatmentinduced mutagenesis would see some resistant mutant
subclones expand rapidly while others are eliminated. The
allelic frequencies of variants therefore would also alter to
varying degrees.
A limitation of this study was its retrospective nature
and the unavailability of normal specimens for germline
analysis from these patients. Four measures were taken
to overcome this limitation while taking full advantage
of these matched initial vs. recurrent tumor sets: (1)
common variants according to the NCBI SNP database
[24] and 1000 genomes MAF data [25] were excluded
to limit analyses to probable disease associated variants
that impact function; (2) deep sequencing was performed
for only previously identified cancer-associated genes
with alterations frequently suggestive of gain- or loss-of-

Figure 3: TMZ-induced mutational events were not evident in the majority of samples at recurrence. (A) Boxplot

representing the distribution of single base substitutions unique to recurrence. The y-axis excludes patient 21 as an outlier with 48 detected
variants. The mean is shown as a circular symbol and the asterisks highlight outliers. (B) An individual value plot presenting the spread
of single base substitutions occurring uniquely at recurrence and the frequency of patients in which they occur. Substitutions detected
in treated patients (including patient 21) and untreated patients are highlighted. (C) Total number of C:G > T:A substitutions and the
proportion of each dinucleotide context.
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Figure 4: Neutral tumor evolution was evident in untreated GBM, however, a shift away from effectively-neutral
subclone dynamics was observed after radiochemotherapy. (A) Boxplot presenting the estimated purity of samples determined

by LUMP analysis. The line of short dashes indicates the 55% purity threshold for inclusion in neutral evolution analyses. (B) The
cumulative distribution M(f) of subclonal mutations in primary tumors prior to therapy analyzed collectively was linear with the inverse of
their frequency (1/f) (upper panel) and a shift away from linearity and therefore neutral evolution was evident in tumors after treatment at
recurrence (lower panel; excludes patient 21 recurrent sample). A stringent R2 > 0.98 defines neutral evolution in these collective analyses.
(C) Subclonal mutations of individual samples were assessed and the variation between tumors at diagnosis and relapse are presented for
the 10 paired samples analyzed. R2 goodness-of-fit measures for the neutral evolution model decrease from diagnosis to recurrence in 80%
of paired samples from the same patient. (D) Boxplot of the R2 goodness-of-fit for the neutral evolution model. Subclonal mutations of
individual samples were assessed and the variation between tumors at diagnosis and relapse are presented for all samples analyzed. The
line of short dashes indicates the R2 = 0.98 threshold used to distinguish neutral and non-neutral evolution. A two-way analysis of variance
was performed using the general linear model for continuous variables and the corresponding p-value is displayed. (E) The cumulative
distribution M(f) of subclonal mutations in the primary tumor (upper panel) and relapse tumor (lower panel) of patient 21. A switch from
neutral to non-neutral evolutionary dynamics was apparent between tumors at diagnosis and relapse.
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functions; (3) neutral evolution analysis assessed subclonal
variants with VAFs of less than 0.25 and therefore the
potential confounding effects of ploidy and low MAF
germline variants were avoided; (4) analyses were
centered around comparing the dynamic mutation profiles
between the primary tumors and their matched recurrent
counterparts (i.e. we did not aim to identify novel cancer
genes). Choice of platform was primarily determined by
the limited material available for processing. The neutral
evolution model posits that the expanding tumor randomly
accumulates a large number of new variants in continually
smaller subclonal fractions. Distinct variants are identified
in different regions, however, they follow the same 1/f
distribution. Whilst a greater breadth of sequencing would
have facilitated a more thorough assessment of variant
dynamics, the comprehensive cancer panel provided a
snapshot view comparing the changes in evolutionary
dynamics in response to treatment rather than a single
timepoint. Additionally, a higher read depth provided
more accurate detection of subclonal variants and ensured
sufficient coverage even in regions with greater sequence
complexity. Future prospective studies including germline
analysis will be needed.
Whilst the size of our cohort was not sufficient to
detect subtle disease pathway associations at the levels

of statistical significance we were able to make several
significant observations. We did observe an increase in
the number of variants with low VAF (< 0.4) in patients
with mutated TP53 at recurrence confirming previous
observations [4]. The variant data presented here have a
number of implications for patients and future approaches
to therapy. Whilst there was a clear molecular response
to therapy with DNA damaging agents, the dynamic and
rapidly evolving nature of variants in GBM conspires
to quickly select clonal populations that are resistant to
these therapies. The majority of patients fail treatment
quickly and succumb to the disease. The median time to
recurrence whilst on treatment of our cohort as an example
was only nine months. These data confirm for those in
the field that such approaches with treatment modalities
using DNA damage are highly unlikely to translate to
long term success in treatment. Additionally, the data are
also suggestive that single targeted therapies using a onedimensional personalized approach are likely to be quickly
overcome through non-neutral evolutionary selection.
An alternative approach using sequential interventions
and a chronic disease therapeutic and management
paradigm may be one consideration. This study also
highlights a need for a concerted effort to advance GBM
research, employing prospectively secured specimens

Figure 5: Interrogation of publically available datasets also indicates a stronger fit to the neutral evolution model
in untreated primary tumors. (A) Boxplot of the R2 goodness-of-fit for the neutral evolution model, presenting data from cohort 2.
The minimum purity level of included samples is categorized below the x-axis and the 93 samples which satisfied inclusion criteria for
analysis using purity-adjusted VAFs are compared. The line of short dashes indicates the R2 = 0.98 threshold used to distinguish neutral and
non-neutral evolution and the number of samples greater than this threshold out of the total number analyzed in each category is indicated
above the dashed line. (B) Boxplot of the R2 goodness-of-fit for the neutral evolution model, presenting data from cohort 3. The line of
short dashes indicates the R2 = 0.98 threshold. A two-way analysis of variance was performed using the general linear model for continuous
variables and the corresponding p-value is displayed.
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and implementing standardized methodologies and data
analysis pipelines.

pub#clinical, download November 2016) [27]. Variant
frequency and purity data was gathered for a further nine
samples from the INCB cohort from the Besta Brain
Biobank, previously published by Wang et al. [5] and
one sample from the SMC cohort from Seoul National
University Hospital, originally reported by Kim et al. [22].

MATERIALS AND METHODS
Biospecimen and data acquisition

DNA extraction

Formalin-fixed paraffin-embedded (FFPE) tumor
samples were obtained from the Royal Melbourne Hospital
(RMH) and University of Melbourne, Department of
Surgery Brain Tumor Bank. Tissue was collected after
informed consent during surgical resection at diagnosis
and recurrence, and matched clinical data was obtained
from the Australian Comprehensive Cancer Outcomes
and Research Database (ACCORD). Specimen use was
approved by the Melbourne Health Human Research
Ethics Committee (HREC; 2013.084) and research was
approved by the Monash Health HREC (1301A), with
subsequent site approvals by the Deakin University
(2013–124) and Barwon Health HRECs (13/16).
Additional data on GBM samples from publicly
available datasets were interrogated for VAF and purity
information. The NCI Genomic Data Commons (GDC)
[26] portal was used to access the MuTect masked somatic
mutation MAF file format of the TCGA-GBM dataset
(https://gdc-portal.nci.nih.gov/projects/TCGA-GBM,
download November 2016). ABSOLUTE purity levels
for the dataset were collated from the cBioPortal for
Cancer Genomics merged cohort of LGG and GBM data
file (http://www.cbioportal.org/study?id=lgggbm_tcga_

Genomic DNA was extracted from tumor tissue
using the ReliaPrep™ FFPE gDNA Miniprep System
(Promega), as directed by the manufacturer. The
quality of the DNA was assessed using a nanodrop
spectrophotometer and quantified using a Qubit®
dsDNA HS Assay kit and a Qubit® 2.0 Fluorometer
(ThermoFisher).

Targeted sequencing
Multiplexed targeted sequencing was performed
using the Ion AmpliSeq™ Comprehensive Cancer Panel
which interrogates 409 cancer associated genes, utilizing
16000 primer pairs in four pools. Barcoded libraries were
prepared using 10 ng of gDNA per primer pool and the
Ion AmpliSeq™ Library Kit 2.0 (Life Technologies),
as directed by the manufacturer. Template preparation
and sequencing was conducted by the MHTP Medical
Genomics Facility (Melbourne, Australia). Amplified
libraries were quantified using an Agilent® 2100
Bioanalyzer and combined equally to a final concentration

Figure 6: Neutral expansion of variants shifts toward non-neutral modes after therapy. Pictorial representation of the

neutral expansion of subclones and the linear accumulation of variants M(f) with the inverse of their frequency f. An R2 equal to 1.0 depicts
precisely neutral evolutionary dynamics. With the applied pressure of therapy subclonal expansion becomes altered and variable. Some
resistant clones and clones with treatment-induced mutations experience a growth advantage and expand rapidly, while other treatmentsensitive clones are reduced or eliminated. The allelic frequency of some variants increases at a more rapid rate while others are decreased.
Non-neutral modes of subclonal variant expansion dominate.
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of 100 pM for template preparation with the Ion PI™
Template OT2 200 Kit v3. Libraries were sequenced on an
Ion Proton™ system using the Ion PI™ Sequencing 200
kit v3 and four samples (16 libraries) were loaded onto
each Ion PI™ chip v2.

were scrutinized to ensure that a single outlying data
point did not heavily influence the slope of the fitted
line and alter the detection of neutral or non-neutral
evolution. Due to the targeted nature of this high-depth
sequencing analysis, fewer subclonal variants available
to fit the model may undercall neutrality when individual
specimens are analyzed [6]. Assessment of publicly
available data was limited to samples with less than or
equal to 45% normal contamination as determined by
ABSOLUTE purity values. Due to the lower depth of
sequencing, only samples with a minimum count of 12
subclonal variants with purity-adjusted allele frequencies
greater than or equal to 0.10 or less than 0.25 were
considered.
Consideration of SIFT [11] and PROVEAN [12]
scores was used for the prediction of the functional impact
of exonic variants.

Data processing and variant identification
For cohort 1, sequencing reads were aligned to the
Human hg19 reference sequence (Build 37) and variant
calling was performed using the Ion Torrent Software
Suite 4.0.2 and the Somatic-Proton-Low Stringency
Variant Caller Plugin v4.0-r76860. Ion Reporter™
Software v4.6 was used for variant annotation
and functional prediction and the Broad Institute
Integrative Genomics Viewer (IGV) was used for
manual visualization and exclusion of some variants.
On average 21 million mapped reads (range 12.4–28.3
million) with a mean read length of 108 bp (range
103–112) were generated and were 99% on-target.
A mean read depth of 1272 (range 769–1697 reads)
was achieved with an average of 81% uniformity of
coverage (range 69–91%). Overall, 89% of bases were
called with a predicted quality score of at least 20 (Q ≥
20), encompassing 2 × 109 bases (range 1.3 × 109–2.7
× 109 bases). Stringent quality, coverage and frequency
metrics were applied to detected variants to restrict
analyses to high confidence variants and eliminate
possible sequencing artefacts [28]. The filtering criteria
used selected variant calls with p-values of less than
0.05, quality scores of at least 20 (Q20), coverage of
greater than 100 reads, allele read counts of at least 50
reads, and VAFs of at least 8%. Common variants with a
minor allele frequency, according to the 1000 genomes
database, of greater than 5% were also excluded to
limit analyses to probable disease associated variants
that impact function. Variants that occurred in more
than 50% of patients were excluded as likely artefacts.
The cBioPortal for Cancer Genomics OncoPrinter was
used to generate OncoPrints of key pathway variants
[29, 30].
A neutral evolution model was applied to variant
data as detailed previously [6]. Briefly, the total SNVs
detected within tumor specimens, limited to samples
with less than or equal to 45% normal contamination as
determined by leukocyte unmethylation to infer tumor
purity (LUMP) analysis and variants with purity-adjusted
allele frequencies greater than 0.10 and less than 0.25,
encompassing subclonal variants reliably detected by
high-throughput sequencing, were used to fit the model.
Therefore clonal events and the potential confounding
effects of ploidy and low MAF germline variants,
which would occur at VAFs greater than 0.25, were
eliminated. A stringent threshold of R2 > 0.98 was used
for defining the goodness-of-fit to the neutral evolution
model. In samples with fewer than 10 variants, results
www.impactjournals.com/oncotarget

Variant validation
A semi-selected validation approach was
undertaken, focusing on coding variants in genes involved
in the key signaling pathways altered in GBM. In order to
be reliably detected by Sanger sequencing only variants
with an allele frequency greater than 20% were sequenced
(primer details Supplementary Table 5). These totaled 46
variants, including 36 SNVs and 10 small insertions and
deletions (INDELs) and involved the sequencing of 138
out of the 5357 (2.6%) variants detected overall. Similar
to other studies [3, 4, 31], validation rates for SNVs and
INDELs were 94% and 50% respectively, achieving an
overall variant validation rate of 85%.

DNA methylation analysis of MGMT
Genomic DNA was prepared for analysis using
the MethyEasy™ Bisulphite Kit (Genetic signatures)
and subsequent processing was undertaken by The
Centre for Applied Genomics, The Hospital for Sick
Children (Toronto, Canada) as per manufacturer’s
instructions. Four samples were replicated on dual
array processing runs to assess the reproducibility of
the arrays. Data for each replicate sample correlated
well (average R2 = 0.952; range 0.904–0.986). The
methylation status of MGMT was determined by
assessing both the beta value determined for probe
cg12981137, which detects the level of methylation at
a CpG site within a distinct region of MGMT exon 1
found to be most strongly associated with expression
[32], and the mean beta value across all 12 available
probes corresponding to sites in the promoter region of
MGMT. Samples with a beta value above a threshold of
0.2 as described previously [33] for probe cg12981137
that also correlated with a mean beta value above this
threshold across all 12 sites within the promoter region
were considered methylated.
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All statistical analyses were conducted using
the Minitab® v17.1.0 software package. A two-way
analysis of variance was performed using the general
linear model for continuous variables. Initially a
test for the interaction of factors was included. If no
significant interaction was identified the test was rerun without the interaction terms. The response, the
number of variants, was examined against and adjusted
for treatment and sample type or whether a variant
was shared or unique between matched samples. The
F-value F(df effect, df error) and T-value t(df) are
also reported where appropriate. Similar analyses
were undertaken to examine the differences in variant
numbers with specific single base substitutions and
between neutral evolution R2 model fit values. Post-hoc
pairwise comparisons were conducted using the Tukey
method. The Grubbs’ test was used to detect outliers
in the data set. The null hypothesis that there were no
outliers was rejected at the 0.05 significance level.
The differences between the number of tumors
adhering to the neutral evolution model at diagnosis
and relapse were also assessed using a one-sample t-test
against the threshold value of R2 = 0.98. A similar analysis
was undertaken to compare the mean R2 model fit values
of each group to R2 = 0.96. For all analyses a p-value less
than or equal to 0.05 was considered to indicate statistical
significance.
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